Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MGTX

MGTX - MeiraGTx Holdings plc Stock Price, Fair Value and News

$7.40-0.24 (-3.14%)
Market Closed

7/100

MGTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

MGTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

MGTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MGTX Price Action

Last 7 days

5.7%

Last 30 days

-0.8%

Last 90 days

-17.0%

Trailing 12 Months

-10.3%

MGTX RSI Chart

MGTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MGTX Valuation

Market Cap

595.6M

Price/Earnings (Trailing)

-14.41

Price/Sales (Trailing)

956.19

EV/EBITDA

-20.17

Price/Free Cashflow

-4.92

MGTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

MGTX Fundamentals

MGTX Revenue

Revenue (TTM)

697.0K

Rev. Growth (Yr)

-96.24%

Rev. Growth (Qtr)

-88.89%

MGTX Earnings

Earnings (TTM)

-41.3M

Earnings Growth (Yr)

-28.43%

Earnings Growth (Qtr)

-30.2%

MGTX Profitability

EBT Margin

-6843.64%

Return on Equity

101.93%

Return on Assets

-21.82%

Free Cashflow Yield

-20.32%

MGTX Investor Care

Shares Dilution (1Y)

2.99%

Diluted EPS (TTM)

-2.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202411.4M8.1M13.9M697.0K
202315.4M15.0M14.5M14.0M
202238.7M44.4M42.3M15.9M
202115.9M18.6M20.4M37.7M
202016.7M17.2M18.7M15.6M
201900013.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About MeiraGTx Holdings plc

MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
 CEO
 WEBSITEhttps://meiragtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES406

MeiraGTx Holdings plc Frequently Asked Questions

MGTX is the stock ticker symbol of MeiraGTx Holdings plc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of MeiraGTx Holdings plc is 595.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, MGTX's PE ratio (Price to Earnings) is -14.41 and Price to Sales (PS) ratio is 956.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGTX PE ratio will change depending on the future growth rate expectations of investors.